|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maheshwari V and Moser AJ: Current
management of locally advanced pancreatic cancer. Nat Clin Pract
Gastroenterol Hepatol. 2:356–364. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang Z, Li Y, Ahmad A, Banerjee S, Azmi
AS, Kong D and Sarkar FH: Pancreatic cancer: Understanding and
overcoming chemoresistance. Nat Rev Gastroenterol Hepatol. 8:27–33.
2011. View Article : Google Scholar
|
|
4
|
Goodman KA and Hajj C: Role of radiation
therapy in the management of pancreatic cancer. J Surg Oncol.
107:86–96. 2013. View Article : Google Scholar
|
|
5
|
Mahalingam D, Kelly KR, Swords RT, Carew
J, Nawrocki ST and Giles FJ: Emerging drugs in the treatment of
pancreatic cancer. Expert Opin Emerg Drugs. 14:311–328. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cunningham D, Chau I, Stocken DD, Valle
JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J,
et al: Phase III randomized comparison of gemcitabine versus
gemcitabine plus capecitabine in patients with advanced pancreatic
cancer. J Clin Oncol. 27:5513–5518. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Herrmann R, Bodoky G, Ruhstaller T,
Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A,
Pestalozzi B, et al: Gemcitabine plus capecitabine compared with
gemcitabine alone in advanced pancreatic cancer: A randomized,
multicenter, phase III trial of the Swiss group for clinical cancer
research and the central European cooperative oncology group. J
Clin Oncol. 25:2212–2217. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Steinhardt AA, Gayyed MF, Klein AP, Dong
J, Maitra A, Pan D, Montgomery EA and Anders RA: Expression of
Yes-associated protein in common solid tumors. Hum Pathol.
39:1582–1589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT,
Zender L, Lowe SW, Poon RT and Luk JM: Yes-associated protein is an
independent prognostic marker in hepatocellular carcinoma. Cancer.
115:4576–4585. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kapoor A, Yao W, Ying H, Hua S, Liewen A,
Wang Q, Zhong Y, Wu CJ, Sadanandam A, Hu B, et al: Yap1 activation
enables bypass of oncogenic kras addiction in pancreatic cancer.
Cell. 158:185–197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zender L, Spector MS, Xue W, Flemming P,
Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, et
al: Identification and validation of oncogenes in liver cancer
using an integrative oncogenomic approach. Cell. 125:1253–1267.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee KP, Lee JH, Kim TS, Kim TH, Park HD,
Byun JS, Kim MC, Jeong WI, Calvisi DF, Kim JM and Lim DS: The
Hippo-Salvador pathway restrains hepatic oval cell proliferation,
liver size, and liver tumorigenesis. Proc Natl Acad Sci USA.
107:8248–8253. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang XY, Ke AW, Shi GM, Zhang X, Zhang C,
Shi YH, Wang XY, Ding ZB, Xiao YS, Yan J, et al: αB-crystallin
complexes with 14-3-3ζ to induce epithelial-mesenchymal transition
and resistance to sorafenib in hepatocellular carcinoma.
Hepatology. 57:2235–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Feng X, Degese MS, Iglesias-Bartolome R,
Vaque JP, Molinolo AA, Rodrigues M, Zaidi MR, Ksander BR, Merlino
G, Sodhi A, et al: Hippo-Independent Activation of YAP by the GNAQ
uveal melanoma oncogene through a trio-regulated rho GTPase
signaling circuitry. Cancer Cell. 25:831–845. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang W, Nandakumar N, Shi Y, Manzano M,
Smith A, Graham G, Gupta S, Vietsch EE, Laughlin SZ, Wadhwa M, et
al: Downstream of mutant KRAS, the transcription regulator YAP is
essential for neoplastic progression to pancreatic ductal
adenocarcinoma. Sci Signal. 7:ra422014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Muramatsu T, Imoto I, Matsui T, Kozaki K,
Haruki S, Sudol M, Shimada Y, Tsuda H, Kawano T and Inazawa J: YAP
is a candidate oncogene for esophageal squamous cell carcinoma.
Carcinogenesis. 32:389–398. 2011. View Article : Google Scholar
|
|
17
|
Wang LJ, Shi SJ, Guo ZY, Zhang X, Han S,
Yang A, Wen W and Zhu Q: Overexpression of YAP and TAZ Is an
independent predictor of prognosis in colorectal cancer and related
to the proliferation and metastasis of colon cancer cells. Plos
One. 8:e655392013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kang W, Tong JH, Chan AW, Lee TL, Lung RW,
Leung PP, So KK, Wu K, Fan D, Yu J, et al: Yes-associated protein 1
exhibits oncogenic property in gastric cancer and its nuclear
accumulation associates with poor prognosis. Clin Cancer Res.
17:2130–2139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Y, Dong Q, Zhang Q, Li Z, Wang E and
Qiu X: Overexpression of yes-associated protein contributes to
progression and poor prognosis of non-small-cell lung cancer.
Cancer Sci. 101:1279–1285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hall CA, Wang R, Miao J, Oliva E, Shen X,
Wheeler T, Hilsenbeck SG, Orsulic S and Goode S: Hippo pathway
effector Yap is an ovarian cancer oncogene. Cancer Res.
70:8517–8525. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao B, Tumaneng K and Guan KL: The Hippo
pathway in organ size control, tissue regeneration and stem cell
self-renewal. Nat Cell Biol. 13:877–883. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang H, Du YC, Zhou XJ, Liu H and Tang SC:
The dual functions of YAP-1 to promote and inhibit cell growth in
human malignancy. Cancer Metastasis Rev. 33:173–181. 2014.
View Article : Google Scholar
|
|
23
|
Wang H, Zhou M, Shi B, Zhang Q, Jiang H,
Sun Y, Liu J, Zhou K, Yao M, Gu J, et al: Identification of an exon
4-deletion variant of epidermal growth factor receptor with
increased metastasis-promoting capacity. Neoplasia. 13:461–471.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao Q, Zhao YJ, Wang XY, Qiu SJ, Shi YH,
Sun J, Yi Y, Shi JY, Shi GM, Ding ZB, et al: CXCR6 upregulation
contributes to a proinflammatory tumor microenvironment that drives
metastasis and poor patient outcomes in hepatocellular carcinoma.
Cancer Res. 72:3546–3556. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hwang JH, Pores Fernando AT, Faure N,
Andrabi S, Adelmant G, Hahn WC, Marto JA, Schaffhausen BS and
Roberts TM: Polyoma small T antigen interacts with Yes-associated
protein to regulate cell survival and differentiation. J Virol.
88:12055–12064. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tao J, Calvisi DF, Ranganathan S, Cigliano
A, Zhou L, Singh S, Jiang L, Fan B, Terracciano L, Armeanu-Ebinger
S, et al: Activation of β-catenin and Yap1 in human hepatoblastoma
and induction of hepatocarcinogenesis in mice. Gastroenterology.
147:690–701. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fu D, Lv X, Hua G, He C, Dong J, Lele SM,
Li DW, Zhai Q, Davis JS and Wang C: YAP regulates cell
proliferation, migration, and steroidogenesis in adult granulosa
cell tumors. Endoc Relat Cancer. 21:297–310. 2014. View Article : Google Scholar
|
|
28
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Acloque H, Adams MS, Fishwick K,
Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions:
The importance of changing cell state in development and disease. J
Clin Invest. 119:1438–1449. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zeisberg M and Neilson EG: Biomarkers for
epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chang TH, Tsai MF, Su KY, Wu SG, Huang CP,
Yu SL, Yu YL, Lan CC, Yang CH, Lin SB, et al: Slug confers
resistance to the epidermal growth factor receptor tyrosine kinase
inhibitor. Am J Respir Crit Care Med. 183:1071–1079. 2011.
View Article : Google Scholar
|
|
33
|
Saxena M, Stephens MA, Pathak H and
Rangarajan A: Transcription factors that mediate
epithelial-mesenchymal transition lead to multidrug resistance by
upregulating ABC transporters. Cell Death Dis. 2:e1792011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang Z, Li Y, Ahmad A, Azmi AS, Kong D,
Banerjee S and Sarkar FH: Targeting miRNAs involved in cancer stem
cell and EMT regulation: An emerging concept in overcoming drug
resistance. Drug Resist Updat. 13:109–118. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nath S, Daneshvar K, Roy LD, Grover P,
Kidiyoor A, Mosley L, Sahraei M and Mukherjee P: MUC1 induces drug
resistance in pancreatic cancer cells via upregulation of multidrug
resistance genes. Oncogenesis. 2:e512013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hu H, Gu Y, Qian Y, Hu B, Zhu C, Wang G
and Li J: DNA-PKcs is important for Akt activation and gemcitabine
resistance in PANC-1 pancreatic cancer cells. Biochem Biophys Res
Commun. 452:106–111. 2014. View Article : Google Scholar : PubMed/NCBI
|
